The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study
The life expectancy of patients with psychotic disorders is significantly shorter than that of the general population; antipsychotic-induced metabolic disorders play a significant role in reducing life expectancy. Both metabolic syndrome (MetS) and schizophrenia are multifactorial conditions. One ar...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/7/941 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849251887588573184 |
|---|---|
| author | Irina A. Mednova Ekaterina V. Mikhalitskaya Natalia M. Vyalova Diana Z. Paderina Dmitry A. Petkun Vladimir V. Tiguntsev Elena G. Kornetova Nikolay A. Bokhan Svetlana A. Ivanova |
| author_facet | Irina A. Mednova Ekaterina V. Mikhalitskaya Natalia M. Vyalova Diana Z. Paderina Dmitry A. Petkun Vladimir V. Tiguntsev Elena G. Kornetova Nikolay A. Bokhan Svetlana A. Ivanova |
| author_sort | Irina A. Mednova |
| collection | DOAJ |
| description | The life expectancy of patients with psychotic disorders is significantly shorter than that of the general population; antipsychotic-induced metabolic disorders play a significant role in reducing life expectancy. Both metabolic syndrome (MetS) and schizophrenia are multifactorial conditions. One area where the two conditions overlap is oxidative stress, which is present in both diseases. The glutathione-S-transferase (GST) system is a major line of defense against exogenous toxicants and oxidative damage to cells. The aim of our study was to perform an association analysis of gene polymorphisms with metabolic disorders in patients with schizophrenia treated with antipsychotic therapy. <b>Methods</b>: A total of 639 white patients with schizophrenia (ICD-10) from Siberia (Russia) were included in the study. Genotyping was carried out using real-time polymerase chain reaction for two single-nucleotide polymorphisms (SNPs) in the <i>GSTP1</i> (rs614080 and rs1695) and one SNP in the <i>GSTO1</i> (rs49252). <b>Results</b>: We found that rs1695*GG genotype of <i>GSTP1</i> is a risk factor for the development of overweight (OR 2.36; 95% CI: 1.3–4.29; <i>p</i> = 0.0054). In the subgroup of patients receiving first-generation antipsychotics as basic therapy, the risk of overweight was associated with carriage of the rs1695*GG (OR 5.43; 95% CI: 2.24–13.16; <i>p</i> < 0.001) genotype of <i>GSTP1</i> in a recessive model of inheritance. In contrast, an association of rs1695*G GSTP1 with obesity (OR: 0.42; 95% CI: 0.20–0.87; <i>p</i> = 0.018) was shown in the dominant model of inheritance in patients receiving second-generation antipsychotics. <b>Conclusions</b>: The pilot results obtained confirm the hypothesis of a violation of the antioxidant status, in particular the involvement of <i>GSTP1,</i> in the development of antipsychotic-induced metabolic disorders in schizophrenia. Further studies with larger samples and different ethnic groups are needed to confirm the obtained results. |
| format | Article |
| id | doaj-art-c44a29b5331a4350b09bbcc75458a375 |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-c44a29b5331a4350b09bbcc75458a3752025-08-20T03:56:47ZengMDPI AGPharmaceuticals1424-82472025-06-0118794110.3390/ph18070941The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot StudyIrina A. Mednova0Ekaterina V. Mikhalitskaya1Natalia M. Vyalova2Diana Z. Paderina3Dmitry A. Petkun4Vladimir V. Tiguntsev5Elena G. Kornetova6Nikolay A. Bokhan7Svetlana A. Ivanova8Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaMental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, RussiaThe life expectancy of patients with psychotic disorders is significantly shorter than that of the general population; antipsychotic-induced metabolic disorders play a significant role in reducing life expectancy. Both metabolic syndrome (MetS) and schizophrenia are multifactorial conditions. One area where the two conditions overlap is oxidative stress, which is present in both diseases. The glutathione-S-transferase (GST) system is a major line of defense against exogenous toxicants and oxidative damage to cells. The aim of our study was to perform an association analysis of gene polymorphisms with metabolic disorders in patients with schizophrenia treated with antipsychotic therapy. <b>Methods</b>: A total of 639 white patients with schizophrenia (ICD-10) from Siberia (Russia) were included in the study. Genotyping was carried out using real-time polymerase chain reaction for two single-nucleotide polymorphisms (SNPs) in the <i>GSTP1</i> (rs614080 and rs1695) and one SNP in the <i>GSTO1</i> (rs49252). <b>Results</b>: We found that rs1695*GG genotype of <i>GSTP1</i> is a risk factor for the development of overweight (OR 2.36; 95% CI: 1.3–4.29; <i>p</i> = 0.0054). In the subgroup of patients receiving first-generation antipsychotics as basic therapy, the risk of overweight was associated with carriage of the rs1695*GG (OR 5.43; 95% CI: 2.24–13.16; <i>p</i> < 0.001) genotype of <i>GSTP1</i> in a recessive model of inheritance. In contrast, an association of rs1695*G GSTP1 with obesity (OR: 0.42; 95% CI: 0.20–0.87; <i>p</i> = 0.018) was shown in the dominant model of inheritance in patients receiving second-generation antipsychotics. <b>Conclusions</b>: The pilot results obtained confirm the hypothesis of a violation of the antioxidant status, in particular the involvement of <i>GSTP1,</i> in the development of antipsychotic-induced metabolic disorders in schizophrenia. Further studies with larger samples and different ethnic groups are needed to confirm the obtained results.https://www.mdpi.com/1424-8247/18/7/941<i>GSTP1</i>metabolic syndromeBMIschizophreniapolymorphic variantspharmacogenetics |
| spellingShingle | Irina A. Mednova Ekaterina V. Mikhalitskaya Natalia M. Vyalova Diana Z. Paderina Dmitry A. Petkun Vladimir V. Tiguntsev Elena G. Kornetova Nikolay A. Bokhan Svetlana A. Ivanova The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study Pharmaceuticals <i>GSTP1</i> metabolic syndrome BMI schizophrenia polymorphic variants pharmacogenetics |
| title | The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study |
| title_full | The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study |
| title_fullStr | The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study |
| title_full_unstemmed | The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study |
| title_short | The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study |
| title_sort | role of gst gene polymorphic variants in antipsychotic induced metabolic disorders in schizophrenia a pilot study |
| topic | <i>GSTP1</i> metabolic syndrome BMI schizophrenia polymorphic variants pharmacogenetics |
| url | https://www.mdpi.com/1424-8247/18/7/941 |
| work_keys_str_mv | AT irinaamednova theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT ekaterinavmikhalitskaya theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT nataliamvyalova theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT dianazpaderina theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT dmitryapetkun theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT vladimirvtiguntsev theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT elenagkornetova theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT nikolayabokhan theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT svetlanaaivanova theroleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT irinaamednova roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT ekaterinavmikhalitskaya roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT nataliamvyalova roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT dianazpaderina roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT dmitryapetkun roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT vladimirvtiguntsev roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT elenagkornetova roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT nikolayabokhan roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy AT svetlanaaivanova roleofgstgenepolymorphicvariantsinantipsychoticinducedmetabolicdisordersinschizophreniaapilotstudy |